Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...

An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in ...

Leqembi is an infusion therapy approved by the Food and Drug Administration in 2023. It targets and removes the beta-amyloid ...

Within the past few years, the FDA approved two groundbreaking drugs that in trials were shown to reduce brain plaque by 27% ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of blockbuster treatments, Mounjaro and Zepbound. Where to invest $1,000 right now?

Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's small impact on slowing cognitive decline was not large enough to outweigh the risk of ...

A key theme at the AD/PD 2025 has been the safety profile of DMTs, focusing on the issue of ARIA, a significant side effect ...

The legislation would require insurance plans provided through the state’s system to cover FDA-approved treatments for ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible brain swelling and bleeding. Although the drug is alr ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...